Genmab A/S (NASDAQ:GMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Genmab A/S (NASDAQ:GMAB) has received an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $41.33.

A number of brokerages recently issued reports on GMAB. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Thursday, February 13th. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Truist Financial decreased their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $19.90 on Friday. The company has a market cap of $13.17 billion, a price-to-earnings ratio of 11.44, a PEG ratio of 2.65 and a beta of 0.98. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $30.50. The stock has a fifty day moving average price of $20.89 and a 200-day moving average price of $21.88.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Research analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds have recently modified their holdings of GMAB. Charles Schwab Investment Management Inc. raised its position in Genmab A/S by 94.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock worth $636,000 after purchasing an additional 12,654 shares during the last quarter. AIMZ Investment Advisors LLC acquired a new stake in shares of Genmab A/S in the fourth quarter valued at about $3,525,000. HighTower Advisors LLC bought a new position in shares of Genmab A/S during the third quarter worth about $273,000. Verition Fund Management LLC acquired a new position in shares of Genmab A/S in the third quarter worth approximately $709,000. Finally, FMR LLC boosted its holdings in Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after acquiring an additional 33,076 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.